NCT00502710View on ClinicalTrials.gov

A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in Patients With Type 2 Diabetes.

PHASE2CompletedINTERVENTIONAL
Enrollment

289

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

Placebo

Placebo po daily.

DRUG

RO4876904

Escalating doses, at a starting dose of 12.5mg po daily.

Trial Locations (48)

2065

St Leonards

2605

Canberra

5000

Adelaide

11650

Mexico City

13901

Binghamton

15009

Beaver

15405

Ferrol

20230

Aguascalientes

20745

Oxon Hill

28211

Charlotte

31238

Chihuahua City

42086

Pachuca

44650

Guadalajara

45200

Guadalajara

46123

Avon

46260

Indianapolis

46600

Alzira

48098

Troy

60607

Chicago

68154

Omaha

71913

Hot Springs

89109

Tampico

90057

Los Angeles

94520

Concord

109263

Moscow

117036

Moscow

121069

Moscow

125315

Moscow

129110

Moscow

150010

Yaroslavl

150062

Yaroslavl

195112

Saint Petersburg

195213

Saint Petersburg

197089

Saint Petersburg

197198

Saint Petersburg

410038

Saratov

01244-030

São Paulo

04022-001

São Paulo

01015

Guatemala City

Unknown

Hong Kong

Badalona

03114

Bacarot Alicant

08022

Barcelona

BA1 2SR

Bath

BA11 1EZ

Frome

G45 9AW

Glasgow

L9 7AL

Liverpool

ML1 3JX

Motherwell

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00502710 - A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in Patients With Type 2 Diabetes. | Biotech Hunter | Biotech Hunter